Literature DB >> 29324670

Dietary Carotenoid Intakes and Prostate Cancer Risk: A Case-Control Study from Vietnam.

Dong Van Hoang1, Ngoc Minh Pham2,3, Andy H Lee4, Duong Nhu Tran5, Colin W Binns6.   

Abstract

The incidence of prostate cancer has increased in Vietnam, but there have been few studies of the risk factors associated with this change. This retrospective case-control study investigated the relation of the intake of carotenoids and their food sources to prostate cancer risk. A sample of 652 participants (244 incident prostate cancer patients, aged 64-75 years, and 408 age frequency-matched controls) were recruited in Ho Chi Minh City during 2013-2015. The habitual diet was ascertained with a validated food-frequency questionnaire, and other factors including demographic and lifestyle characteristics were assessed via face-to-face interviews by trained nurses. Multivariate-adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression models. The risk of prostate cancer decreased with increasing intakes of lycopene, tomatoes, and carrots; the respective ORs (95% CIs) were 0.46 (0.27, 0.77), 0.39 (0.23, 0.66), and 0.35 (0.21, 0.58), when comparing the highest with the lowest tertile of intake (p for trend < 0.01). No statistically significant associations were found for the intake of α-carotene, β-carotene, β-cryptoxanthin, lutein, zeaxanthin, and major food sources of carotenoids. In conclusion, Vietnamese men with a higher intake of lycopene, tomatoes, and carrots may have a lower risk of prostate cancer. However, large prospective studies are needed in this population to confirm this finding.

Entities:  

Keywords:  Vietnam; carotenoids; case-control study; epidemiology; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29324670      PMCID: PMC5793298          DOI: 10.3390/nu10010070

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


1. Introduction

Prostate cancer is globally a common malignancy for males [1]. In developing countries, despite its relatively low prevalence (<20 per 100,000), prostate cancer has shown an increasing trend in recent decades [2]. A healthy diet may play a role in preventing the development of prostate cancer [3]. Accumulated data from epidemiological studies suggested that eating more fruits and vegetables may reduce the risk of prostate cancer [4]. Plant carotenoids, especially carotene and lycopene, are phytochemicals which contribute to that inverse association [5,6,7]. There are multiple mechanisms which may be involved in the bioactivity of these compounds in relation to prostate cancer development, including protecting the DNA from free radicals [8] and modulating gene expression [9]. However, the epidemiological evidence for the association between the intake of specific carotenoids and the risk of prostate cancer remains inconsistent [10,11,12]. The most commonly studied carotenoids for a potential protective benefit against prostate cancer are lycopene, α-carotene, β-carotene, β-cryptoxanthin, lutein, and zeaxanthin [13]. Among them, lycopene has received the most attention and supportive evidence, followed by β-carotene, while the evidence for other carotenoids is still inconclusive [14,15]. Studies on the relationship between carotenoid intake and prostate cancer risk have largely been conducted in North American and European countries, and corresponding data is scarce in Asian nations [12,15]. It is important to discern whether dietary intakes of carotenoid and their major sources are associated with the risk of prostate cancer among populations with low or middle income, including Vietnamese men who experienced an upward trend in prostate cancer incidence over the past decade [16]. The objective of this paper is to report findings of a case-control study that investigated the association of dietary intakes of major carotenoids and their food sources with the risk of prostate cancer in Vietnam.

2. Materials and Methods

A case-control study of 652 participants was conducted in Ho Chi Minh City, Vietnam, during 2013 and 2015. The cases were histologically confirmed prostate cancer patients, aged 64–75 years, with the diagnosis made within one week before their interview. Of the 272 eligible incident patients, 253 agreed to participate and were consecutively recruited and interviewed. Subsequently, nine patients were excluded because of either missing or implausible information, leaving 244 prostate cancer patients for subsequent analysis. Eligible controls were men who were residing in the same catchment area as the cases and did not report having any severe or malignant condition, or attended the same hospitals for minor health problems (e.g., oral health conditions and minor injuries). They were frequency-matched to the cases by 5 years age groups. Of a total of 700 male residents who were contacted, 429 men consented to participate in the study. However, 62 participants were excluded because of: (1) refusal to provide a blood sample for the prostate specific antigen (PSA) test, or having over 4 ng/mL serum PSA; (2) having malignant or severe chronic diseases. As a result, 367 eligible men were recruited and interviewed. In addition, 120 eligible patients who attended the same hospitals (as the cases) for a health check or for treatment of minor health issues were also approached. Eighty-three of these men gave their consent for the interview. Due to implausible or missing information, a further 28 community-based controls and 14 hospital-based controls were excluded. Finally, 244 cases and 408 controls (339 community-based and 69 hospital-based) were included in the statistical analysis. The collected data consisted of information about dietary intakes, demographic, and lifestyle characteristics, and were obtained through face-to-face interviews using a structured questionnaire. Each interview took about 40 min to complete. In order to maximize the accuracy of the information provided, the participant’s next-of-kin were encouraged to participate in the interview. An information sheet was provided to all participants, and written consent was obtained for every interview. Both interviewers and participants were blinded to the study hypothesis. This study was approved by the Human Research Ethics Committee of Curtin University (approval number: HR 109/2012). The dietary intake was assessed using an 89 item semi-quantitative food frequency questionnaire validated in Vietnamese adults [17], with only minor textual modifications. The recall period for dietary habits was set to three years before the interview. A picture booklet was used to assist participants in estimating the intake amount and portion size of certain food items. Tomato sauce was excluded because it was not commonly used in Vietnam. We estimated intakes (μg/day) of lycopene, α-carotene, β-carotene, β-cryptoxanthin, lutein, and zeaxanthin using the US Department of Agriculture nutrient database [18] because of insufficient data provided by the current Vietnamese Food Composition Tables, except for energy intake (kcal/day). We applied the residual method to adjust for variations in energy intake from carotenoid nutrients [19]. Other exposure measurements included demographic and lifestyle characteristics (e.g., age, marital status, education level, and smoking), medical history (including histological examination of the prostate gland and PSA levels), height, and weight. The questions on life-long physical activity exposure was taken from the study “Life-long physical activity involvement and the risk of ischemic stroke in southern China” [20]. The questions on smoking and alcohol drinking were based on the WHO STEPwise approach to noncommunicable disease risk factor surveillance [21]. The distributions of the study variables were examined by case-control status. Demographic and lifestyle characteristics of the participants, as well as carotenoid intake variables, were compared between case and control groups using a two-sample t-test for continuous variables, and a chi-square test for categorical variables. Because the cases and controls were not individually matched, unconditional logistic regression analyses were performed to ascertain the strength of the association between intakes of carotenoids and major food sources and prostate cancer risk. Independent variables (i.e., carotenoids) were transformed into categorical variables based on tertile distribution of controls [22]. The lowest level of each food and nutrient intake was treated as the reference category. Crude and adjusted odds ratios (OR) and associated 95% confidence intervals (CI) were reported. Tests for linear trend were performed with logistic regression models by assigning an ordinal value (i.e., 1–3) to each tertile of the intake of carotenoids and their food sources in relation to the risk of prostate cancer. Confounding variables included in the logistic regression models were education level (primary, high, and tertiary), marital status (married, never married, or separated), smoking habit (never, former, current), presence of prostate cancer in the first-degree relatives (yes, no), life-long physical activity (never, past active, regular), age (year, continuous), body mass index (kg/m2, continuous), ethanol consumption (g/day, continuous), and total energy intake (kcal/day, continuous). These variables were either established or plausible risk factors according to the literature. Additionally, the cases were categorized into low-medium- (Gleason score ≤ 7) and high-grade (Gleason score 8–10) prostate cancer [23] for subgroup analyses. Tests for heterogeneity were performed to evaluate whether the associations between the intake of carotenoids and their food sources and prostate cancer differed by the grade of the tumors. For these analyses, we separately fitted two multivariate logistic regression models for low-medium-grade and high-grade tumors, and compared the risk coefficients and standard errors in each subgroup [24]. The p-values were obtained from Cochran’s Q statistic with a χ2 distribution and one degree of freedom [25]. All statistical analyses were performed using the R Statistics software version 3.3.3 [26]. A p-value < 0.05 was considered statistically significant.

3. Results

The sample consisted of 408 controls and 244 cases, and the average age of the participants was 68 years. Compared to the controls, the prostate cancer patients were married at a younger age, had fewer children, smoked more tobacco cigarettes, and drank more alcohol, and they had a significantly lower energy intake before the diagnosis. The two groups also differed in terms of educational level and lifetime physical activity, with the cases being less educated and less active than their control counterparts. A first-degree family history of prostate cancer was reported by only seven cases (Table 1).
Table 1

Sample characteristics.

Demographic VariableCase (n = 244)Control (n = 408)p-Value
Age (year), mean (SD)68.7 (7.3)68.0 (5.8)0.155
Age at marriage (year), mean (SD)25.0 (4.9)27.3 (4.9)<0.001
Body mass index (kg/m2), mean (SD)22.0 (3.0)21.9 (3.3)0.913
Waist to hip ratio, mean (SD)0.9 (0.1)0.9 (0.1)0.128
Smoking habit (pack, years), mean (SD)16.2 (20.2)12.8 (14.7)0.025
Ethanol (g/day), mean (SD)22.6 (47.5)14.9 (28.4)0.021
Total energy (kcal/day), mean (SD)1712.0 (642.0)2101.0 (832.0)<0.001
Number of children, n (%)
  ≤3103 (42.2)223 (54.7)
  4–692 (37.7)148 (36.3)<0.001
  ≥749 (20.1)37 (9.0)
Education level, n (%)
  Primary school65 (26.6)72 (17.6)0.019
  High school134 (54.9)261 (64.0)
  Tertiary education45 (18.4)75 (18.4)
Marital status, n (%)
  Married233 (95.5)375 (91.9)0.109
  Never married or separated11 (4.5)33 (8.1)
Smoking history, n (%)
  Never58 (23.8)111 (27.2)0.182
  Former121 (49.6)172 (42.2)
  Current65 (26.6)125 (30.6)
Prostate cancer in the first-degree relatives (yes), n (%)7 (2.9)0 (0.0)0.002
Life-long physical activity, n (%)
  Never200 (82.0)192 (47.1)<0.001
  Past active25 (10.2)102 (25.0)
  Regular19 (7.8)114 (27.9)

† p-value from t-Test or chi-square test. SD: standard deviation.

Table 2 shows that prostate cancer patients reported significantly lower consumption levels of carotenoids than controls (p < 0.05). Similarly, the intake levels of the major sources of carotenoids (e.g., tomato and carrot) were also significantly lower among cases when compared to the controls (p < 0.001).
Table 2

Comparison of the intakes of carotenoids and their major sources between cases and controls.

Nutrient or FoodCase (n = 244)Control (n = 408)p-Value
Lycopene (μg/day), mean (SD)839.6 (1087.2)1356.2 (1527.9)<0.001
α-carotene (μg/day), mean (SD)756.5 (294.7)919.8 (411.3)<0.001
β-carotene (μg/day), mean (SD)4473.4 (2555.0)5491.9 (3472.0)<0.001
β-cryptoxanthin (μg/day), mean (SD)749.2 (420.9)839.6 (557.8)0.019
Lutein and zeaxanthin (μg/day), mean (SD)2147.7 (1325.7)2531.9 (1625.0)0.001
Tomato (g/day), mean (SD)10.9 (21.2)19.6 (28.5)<0.001
Carrot (g/day), mean (SD)1.6 (2.7)3.6 (6.5)<0.001
Pumpkin (g/day), mean (SD)15.1 (16.5)16.9 (18.4)0.193
Sweet potato (g/day), mean (SD)8.0 (17.1)11.5 (27.7)0.042
Watermelon (g/day), mean (SD)14.5 (19.5)19.5 (37.9)0.028
Citrus fruits (g/day), mean (SD)6.1 (17.2)9.2 (22.2)0.048

† p-value from t-Test. SD: standard deviation.

The results of the logistic regression analyses showed that increasing intakes of lycopene, tomato, and carrot were significantly associated with a lower risk of prostate cancer (Table 3). Specifically, the adjusted OR for prostate cancer was 0.46 (95% CI: 0.27, 0.77) when comparing the highest versus the lowest tertile of lycopene intake. Similarly, for the intake of tomato and carrot, the adjusted ORs for prostate cancer were 0.39 (95% CI: 0.23, 0.66) and 0.35 (95% CI: 0.21, 0.58), respectively. These inverse associations were fully accounted for potential covariates, namely education level, marital status, smoking habit, family history of prostate cancer, life-long physical activity, age, body mass index, ethanol consumption, and total energy intake. For other exposures with seemingly increased risk in the second tertile of intake, their p-values when tested for linear trend were not significant, so no conclusion can be drawn. Results remained unchanged in either low-medium- or high-grade prostate cancers (See Appendix A).
Table 3

Crude and adjusted odds ratios and associated 95% confidence intervals of prostate cancer risk for the intakes of carotenoid and their sources.

Nutrient or FoodMean Intake (SD)Case, n (%)Control, n (%)OR (95% CI)Adjusted OR (95% CI)p for Linear Trend
Lycopene (μg/day)
  <648388.9 (109.2)77 (31.6)136 (33.3)1.00 reference1.00 reference
  648–1200809.6 (184.1)124 (50.8)137 (33.6)1.60 (1.11, 2.32)0.83 (0.52, 1.34)0.003
  >12002810.5 (1918.6)43 (17.6)135 (33.1)0.56 (0.36, 0.87)0.46 (0.27, 0.77)
α-carotene (μg/day)
  <743547.7 (135.1)89 (36.5)136 (33.3)1.00 reference1.00 reference
  743–976861.7 (82.7)105 (43.0)136 (33.3)1.18 (0.82, 1.71)1.19 (0.78, 1.83)0.307
  >9761336.9 (367.7)50 (20.5)136 (33.3)0.56 (0.37, 0.85)0.77 (0.47, 1.26)
β-carotene (μg/day)
  <39202841.3 (601.1)74 (30.3)137 (33.6)1.00 reference1.00 reference
  3920–57804672.6 (625.9)120 (49.2)135 (33.1)1.65 (1.13, 2.40)1.41 (0.91, 2.19)0.248
  >57808904.4 (3828.9)50 (20.5)136 (33.3)0.68 (0.44, 1.04)0.73 (0.44, 1.22)
β-Cryptoxanthin (μg/day)
  <539404.8 (102.9)62 (25.4)137 (33.6)1.00 reference1.00 reference
  539–867705.1 (93)100 (41.0)135 (33.1)1.64 (1.10, 2.44)1.63 (1.03, 2.60)0.303
  >8671388.5 (550.8)82 (33.6)136 (33.3)1.33 (0.89, 2.00)1.29 (0.79, 2.09)
Lutein and zeaxanthin (μg/day)
  <16701234.6 (293.3)69 (28.3)137 (33.6)1.00 reference1.00 reference
  1670–25802081.7 (272.9)122 (50.0)135 (33.1)1.79 (1.23, 2.63)1.50 (0.97, 2.34)0.223
  >25804269.3 (1708.0)53 (21.7)136 (33.3)0.77 (0.50, 1.19)0.73 (0.44, 1.20)
Tomato (g/day)
  <7.13.1 (2.1)87 (35.7)136 (33.3)1.00 reference1.00 reference
  7.1–16.510.6 (3.4)114 (46.7)136 (33.3)1.31 (0.91, 1.89)0.68 (0.43, 1.06)<0.001
  >16.547.9 (39.6)43 (17.6)136 (33.3)0.49 (0.32, 0.76)0.39 (0.23, 0.66)
Carrot (g/day)
  <10.4 (0.3)111 (45.5)139 (34.1)1.00 reference1.00 reference
  1–3.22 (0.7)94 (38.5)132 (32.4)0.89 (0.62, 1.28)0.61 (0.39, 0.94)<0.001
  >3.27.8 (8.7)39 (16.0)137 (33.6)0.36 (0.23, 0.55)0.35 (0.21, 0.58)
Pumpkin (g/day)
  <6.43.3 (2.1)69 (28.3)138 (33.8)1.00 reference1.00 reference
  6.4–20.512 (3.6)101 (41.4)135 (33.1)1.50 (1.02, 2.21)1.01 (0.64, 1.59)0.423
  >20.534.5 (19.3)74 (30.3)135 (33.1)1.10 (0.73, 1.64)0.82 (0.51, 1.32)
Sweet potato (g/day)
  <2.40.2 (0.3)51 (20.9)135 (33.1)1.00 reference1.00 reference
  2.4–7.72.3 (0.9)76 (31.1)138 (33.8)1.46 (0.95, 2.24)0.84 (0.49, 1.44)0.291
  >7.722.0 (33.6)117 (48.0)135 (33.1)2.29 (1.53, 3.46)1.32 (0.79, 2.24)
Watermelon (g/day)
  <4.50.7 (0.8)46 (18.9)136 (33.3)1.00 reference1.00 reference
  4.5–17.610.7 (5.9)132 (54.1)137 (33.6)2.85 (1.90, 4.33)2.12 (1.31, 3.45)0.373
  >17.659.9 (56.1)66 (27.0)135 (33.1)1.45 (0.93, 2.27)1.27 (0.76, 2.13)
Citrus fruits (g/day)
  <1.30.2 (0.3)51 (20.9)134 (32.8)1.00 reference1.00 reference
  1.3–62.5 (1.3)133 (54.5)138 (33.8)2.53 (1.70, 3.80)1.74 (1.06, 2.89)0.713
  >621.8 (32.4)60 (24.6)136 (33.3)1.16 (0.74, 1.81)0.91 (0.53, 1.55)

† ORs were adjusted for education level (primary, high, and tertiary), marital status (married, never married, or separated), smoking habit (never, former, current), prostate cancer in the first-degree relatives (yes, no), life-long physical activity (never, past active, regular), age (year), body mass index (kg/m2), ethanol consumption (g/day), and total energy intake (kcal/day); SD: standard deviation; OR: odds ratio; CI: confidence intervals; ‡ based on the adjusted models.

4. Discussion

To the best of our knowledge, this is the first epidemiological study to examine the association between the dietary intake of carotenoids and their major food sources and prostate cancer in the Vietnamese population. In this case-control study, we found that higher intakes of lycopene, tomato, and carrot were significantly associated with a reduced risk of prostate cancer. The inverse associations we observed were dose-responsive and independent of factors commonly associated with prostate cancer, including age, family history of prostate cancer, and body mass index. However, there was a lack of significant association between other dietary carotenoids and foods rich in these phytochemicals and prostate cancer risk. The present data regarding the intake of lycopene is similar to the results of previous studies. A recent meta-analysis of 42 studies showed that participants with the highest level of lycopene intake or blood lycopene had a 12% significantly lower risk of prostate cancer [12] as compared to individuals with the lowest level. It should be noted that the inverse association between lycopene and prostate cancer risk observed in that meta-analysis was restricted to case-control studies and was not observed in prospective studies, consistent with the study by Key et al. [5]. Similarly, another meta-analysis including 34 studies reported an inverse association between lycopene intake or blood levels and the risk of prostate cancer, with a stronger association observed for the circulating lycopene (OR: 0.81; 95% CI: 0.69–0.96) when comparing the highest to the lowest level [15]. Although this study indicated an inverse association between lycopene and prostate cancer risk, large prospective cohort studies with biological samples are needed to confirm our findings because of the lack of conclusive evidence for the lycopeneprostate cancer relationship in the literature. There are some possible pathways through which lycopene may protect against prostate cancer. The antioxidant properties of lycopene can prevent DNA damage by scavenging free radicals [8]. Lycopene can also modulate gene expression related to prostate cancer growth [9,27] and slow cancer cell growth [28]. It has been demonstrated that lycopene inhibits prostate cancer cell proliferation via the PPARγ-LXRα-ABCA1 pathway [29]. Additionally, this non-provitamin A carotenoid was shown to hamper the progression of prostate cancer via apoptosis induction and angiogenesis suppression [30,31]. Tomato is one of the major sources of lycopene [32,33], and the lower risk of prostate cancer observed among men with higher intake of tomato reported here is consistent with previous studies conducted among Western and Asian populations. Pooled data from seven reports in Asia, namely in China, Japan, Malaysia, and Iran, found a strong, inverse association between tomato intake and the risk of prostate cancer (the summary relative risk: 0.43; 95% CI: 0.22–0.85) [34]. Likewise, cooked tomato intake has been shown to decrease prostate cancer risk in a meta-analysis of 21 studies (pooled RR: 0.81; 95% CI: 0.71–0.92) [35]. The mechanism underlying the beneficial effect of dietary tomato on prostate cancer risk can be explained by the high biological activity of lycopene found in tomato (see discussion above). Another possibility is the anticancer effect of phenolic compounds [36] that accounts for the considerable antioxidant properties of tomato [37,38,39,40,41]. Given the popularity of tomatoes in Asia, further evidence from longitudinal studies is required to help an individual make an informed choice perform an informed choice regarding the consumption of tomato for prostate cancer prevention. Carrots (dacus carrota) are commonly consumed worldwide, particularly in Western countries, and are a rich source of α-carotene and β-carotene [36]. Although the consumption of carrots in our study was low compared with others [42], we found a strong dose-responsive inverse association with prostate cancer. Consistent with this finding, a recent meta-analysis including 10 studies (eight case-control and two cohort) showed around 20% significantly lower risk of prostate cancer in the category with the highest level of carrot consumption relative to the one with the lowest level [43]. Because of the scarcity of studies on dietary carrots and prostate cancer risk in Asia [43], our study adds to the evidence for a potentially beneficial role of carrot in prostate cancer prevention among populations, even with a relatively low consumption. The observed inverse association between carrot intake and prostate cancer may be attributable to the bioavailability of carotene abundantly present in carrot [44]. However, neither α-carotene nor β-carotene was related to prostate cancer risk in the present study. The lack of the association between β-carotene and prostate cancer risk is consistent with a recent meta-analysis of 34 studies that found null findings for dietary β-carotene (including 19 studies: the pooled RR: 0.90; 95% CI: 0.81–1.01) and circulating β-carotene (comprising 13 studies: the pooled RR: 0.96; 95% CI: 0.81–1.14) when comparing the highest versus the lowest level of β-carotene [15]. Another individual participant data meta-analysis of 15 studies also demonstrated no statistically significant associations between blood carotene levels and overall prostate cancer risk [5]. Regarding α-carotene, there are inconsistent findings in the available literature on its association with prostate cancer risk. Although the pooled result of 12 studies showed an inverse association between dietary α-carotene intake and overall risk of prostate cancer [15], only two studies [45,46] included in that meta-analysis found a significantly lower risk of prostate cancer in individuals with higher α-carotene intake. Moreover, accumulating data have suggested no evidence for the association between circulating α-carotene and prostate cancer risk [5,15]. Given this, there is a need for conducting long-term clinical trials to elucidate the role of carotene in the development and progression of prostate cancer. β-cryptoxanthin is the major carotenoid in several tropical orange-fleshed fruits and is abundantly found in oranges, tangerines, red pepper, papaya [18]. The predominant sources of lutein and zeaxanthin are spinach, broccoli, brussels sprout, squash, green beans, sweet corn, kale, and lettuce [18]. It has been suggested that these carotenoids have anticarcinogenic activity [47,48]. Nonetheless, similar to dietary carotene intake, we observed no relation between the intake of β-cryptoxanthin as well as lutein and zeaxanthin and prostate cancer risk. Studies reported in the literature are inconclusive with respect to the association between dietary intakes of β-cryptoxanthin, together with lutein and zeaxanthin, and prostate cancer risk. Some studies reported an inverse association for β-cryptoxanthin [45,49,50] or lutein and zeaxanthin [45,50,51], whereas others found null results [51,52,53,54,55]. Moreover, recent pooled findings of 15 individual studies showed that circulating β-cryptoxanthin, lutein, and zeaxanthin were not associated with the risk of prostate cancer (respective summary OR and 95% CI: 0.92 [0.82–1.03], 0.98 [0.86–1.12] and 1.08 [0.92–1.26], comparing the highest versus the lowest levels) [5]. The absence of the association of dietary intakes of beta-cryptoxanthin, lutein, and zeaxanthin, and other food sources (i.e., pumpkin, sweet potato, water melon, and citrus fruits) with the risk of prostate cancer requires confirmation in future studies. There are several limitations to be considered when interpreting the results of the present study. First, a cause–effect relationship between dietary lycopene and its major sources and the risk of prostate cancer cannot be established because of the retrospective cross-sectional design. Second, there are inherent biases for this observational study. A selection bias may have been present as participants were voluntary and not randomly selected from the population. Additionally, controls included some participants who had dental issues, which may have affected food consumption. An information bias, however, was unlikely because all participants were unaware of the study hypothesis, while the role of dietary carotenoids in the development of prostate cancer has not been confirmed, particularly in Vietnam. A recall bias may occur if the cases recalled their history of dietary habits differently from the controls. To minimize the bias and to improve the accuracy of the information obtained, we employed the same well-trained interviewers to conduct direct interviews of both case and control groups using an identical protocol under similar conditions. Information about dietary habit of the study subjects was also sought from the participant’s next-of-kin. Third, we did not measure carotenoids in blood to consolidate the results from the dietary intake; however, the reported correlations between dietary and plasma carotenoids from a recent meta-analysis of 142 studies [56] are weak to moderate (0.26–0.47). Although all selected controls had a PSA level ≤4 ng/mL, a misclassification of their case-control status would still be possible. Indeed, the resulting association should have been weakened, given the low incidence of prostate cancer in Vietnam [57]. Another limitation is that we had only data on the grade of the cancer but not on its stage, and the sample size was not large, which may affect subgroup analyses. Finally, all participants were recruited from the same catchment area within Ho Chi Minh City, and our findings may not be generalizable to the entire Vietnamese population.

5. Conclusions

This case-control study showed an inverse, dose-response association of dietary lycopene, tomato, and carrot with prostate cancer risk among Vietnamese men, despite the lack of association for other dietary carotenoids (i.e., α-carotene, β-carotene, β-cryptoxanthin, as well as lutein and zeaxanthin) and their food sources. Our results add to the evidence for the potentially beneficial role of eating foods rich in lycopene as a possible protection against prostate cancer in Asia. However, the replication of the present study in other locations and a large prospective study in this population would assist in confirming the findings.
Table A1

Associations of the intake of carotenoids and their food sources with the grade of prostate cancer (high: Gleason score 8–10; low-medium: Gleason score ≤ 7).

Nutrient or FoodReference Group ControlsGrade p for Heterogeneity
Low-MediumAdjusted OR (95% CI)HighAdjusted OR (95% CI)
Lycopene (μg/day)
<648136371.00 reference401.00 reference
648–1200137520.65 (0.35, 1.19)721.03 (0.58, 1.86)
>1200135210.36 (0.18, 0.7)220.57 (0.29, 1.12)
p for linear trend 0.003 0.1040.338
α-carotene (μg/day)
<743136381.00 reference511.00 reference
743–976136491.19 (0.69, 2.06)561.19 (0.7, 2.02)
>976136230.72 (0.38, 1.37)270.81 (0.43, 1.5)
p for linear trend 0.322 0.5110.808
β-carotene (μg/day)
<3920137371.00 reference371.00 reference
3920–5780135481 (0.57, 1.76)721.92 (1.11, 3.38)
>5780136250.6 (0.31, 1.12)250.81 (0.42, 1.57)
p for linear trend 0.118 0.4260.511
β-cryptoxanthin (μg/day)
<539137281.00 reference341.00 reference
539–867135461.44 (0.8, 2.62)541.98 (1.1, 3.63)
>867136361.11 (0.6, 2.07)461.53 (0.83, 2.84)
p for linear trend 0.737 reference 0.1780.468
Lutein + zeaxanthin (μg/day)
<1670137351.00 reference341.00 reference
1670–2580135491.15 (0.66, 2)732.2 (1.26, 3.91)
>2580136260.59 (0.31, 1.1)270.88 (0.46, 1.69)
p for linear trend 0.099 0.6840.388
Tomato (g/day)
<7.1137401.00 reference471.00 reference
7.1–16.5135480.64 (0.36, 1.14)660.73 (0.42, 1.26)
>16.5136220.41 (0.21, 0.77)210.38 (0.19, 0.72)
p for linear trend 0.006 0.0030.861
Carrot (g/day)
<1137441.00 reference671.00 reference
1–3.2135480.76 (0.43, 1.32)460.5 (0.29, 0.85)
>3.2136180.36 (0.18, 0.69)210.37 (0.2, 0.68)
p for linear trend 0.003 0.0020.935
Pumpkin (g/day)
<6.4137331.00 reference361.00 reference
6.4–20.5135450.92 (0.52, 1.63)561.19 (0.67, 2.11)
>20.5136320.72 (0.39, 1.32)420.94 (0.52, 1.7)
p for linear trend 0.296 0.8340.543
Sweet potato (g/day)
<2.4137241.00 reference271.00 reference
2.4–7.7135310.71 (0.35, 1.43)451.02 (0.52, 2.04)
>7.7136551.25 (0.64, 2.43)621.43 (0.73, 2.84)
p for linear trend 0.506 0.3040.774
Watermelon (g/day)
<4.5137221.00 reference241.00 reference
4.5–17.6135561.87 (1.01, 3.52)762.43 (1.32, 4.57)
>17.6136321.19 (0.62, 2.33)341.33 (0.68, 2.63)
p for linear trend 0.603 0.4150.819
Citrus fruit (g/day)
<1.3137231.00 reference281.00 reference
1.3–6135591.6 (0.83, 3.13)741.98 (1.06, 3.76)
>6136280.83 (0.42, 1.67)320.93 (0.47, 1.83)
p for linear trend 0.601 0.8090.654

‡ Low-medium grade: Gleason score ≤ 7 and high grade: Gleason score 8–10); † Adjusted for education level (primary, high, and tertiary), marital status (married, never married, or separated), smoking habit (never, former, current), prostate cancer in the first-degree relatives (yes, no), life-long physical activity (never, past active, regular), age (year), body mass index (kg/m2), ethanol consumption (g/day), and total energy intake (kcal/day). CI, confidence interval; OR, odds ratio.

  44 in total

1.  Associations of serum vitamin A and carotenoid levels with markers of prostate cancer detection among US men.

Authors:  Hind A Beydoun; Monal R Shroff; Ravinder Mohan; May A Beydoun
Journal:  Cancer Causes Control       Date:  2011-07-29       Impact factor: 2.506

Review 2.  Epidemiology and prevention of prostate cancer in Vietnam.

Authors:  Hoang Van Dong; Andy H Lee; Nguyen Hoai Nga; Nguyen Quang; Vu Le Chuyen; Colin W Binns
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 3.  Dietary carrot consumption and the risk of prostate cancer.

Authors:  Xin Xu; Yunjiu Cheng; Shiqi Li; Yi Zhu; Xianglai Xu; Xiangyi Zheng; Qiqi Mao; Liping Xie
Journal:  Eur J Nutr       Date:  2014-02-12       Impact factor: 5.614

Review 4.  Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies.

Authors:  Yulan Wang; Ran Cui; Yuanyuan Xiao; Juemin Fang; Qing Xu
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

Review 5.  Dietary polyphenols in prevention and treatment of prostate cancer.

Authors:  Rahul K Lall; Deeba N Syed; Vaqar M Adhami; Mohammad Imran Khan; Hasan Mukhtar
Journal:  Int J Mol Sci       Date:  2015-02-03       Impact factor: 5.923

Review 6.  Tomato consumption and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Xin Xu; Jiangfeng Li; Xiao Wang; Song Wang; Shuai Meng; Yi Zhu; Zhen Liang; Xiangyi Zheng; Liping Xie
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

7.  Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Aurora Perez-Cornago; Ruth C Travis; Paul N Appleby; Konstantinos K Tsilidis; Anne Tjønneland; Anja Olsen; Kim Overvad; Verena Katzke; Tilman Kühn; Antonia Trichopoulou; Eleni Peppa; Maria Kritikou; Sabina Sieri; Domenico Palli; Carlotta Sacerdote; Rosario Tumino; H B As Bueno-de-Mesquita; Antonio Agudo; Nerea Larrañaga; Elena Molina-Portillo; Eva Ardanaz; Maria-Dolores Chirlaque; Cristina Lasheras; Pär Stattin; Maria Wennberg; Isabel Drake; Johan Malm; Julie A Schmidt; Kay-Tee Khaw; Marc Gunter; Heinz Freisling; Inge Huybrechts; Dagfinn Aune; Amanda J Cross; Elio Riboli; Timothy J Key
Journal:  Int J Cancer       Date:  2017-05-15       Impact factor: 7.396

8.  Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Authors:  Timothy J Key; Paul N Appleby; Ruth C Travis; Demetrius Albanes; Anthony J Alberg; Aurelio Barricarte; Amanda Black; Heiner Boeing; H Bas Bueno-de-Mesquita; June M Chan; Chu Chen; Michael B Cook; Jenny L Donovan; Pilar Galan; Rebecca Gilbert; Graham G Giles; Edward Giovannucci; Gary E Goodman; Phyllis J Goodman; Marc J Gunter; Freddie C Hamdy; Markku Heliövaara; Kathy J Helzlsouer; Brian E Henderson; Serge Hercberg; Judy Hoffman-Bolton; Robert N Hoover; Mattias Johansson; Kay-Tee Khaw; Irena B King; Paul Knekt; Laurence N Kolonel; Loic Le Marchand; Satu Männistö; Richard M Martin; Haakon E Meyer; Alison M Mondul; Kristin A Moy; David E Neal; Marian L Neuhouser; Domenico Palli; Elizabeth A Platz; Camille Pouchieu; Harri Rissanen; Jeannette M Schenk; Gianluca Severi; Meir J Stampfer; Anne Tjønneland; Mathilde Touvier; Antonia Trichopoulou; Stephanie J Weinstein; Regina G Ziegler; Cindy Ke Zhou; Naomi E Allen
Journal:  Am J Clin Nutr       Date:  2015-10-07       Impact factor: 7.045

9.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

10.  Global assessment of select phytonutrient intakes by level of fruit and vegetable consumption.

Authors:  Mary M Murphy; Leila M Barraj; Judith H Spungen; Dena R Herman; R Keith Randolph
Journal:  Br J Nutr       Date:  2014-08-11       Impact factor: 3.718

View more
  7 in total

Review 1.  Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis.

Authors:  Filipe Cirne; Coralea Kappel; Shijie Zhou; Som D Mukherjee; Mahshid Dehghan; Jo-Anne Petropoulos; Darryl P Leong
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-05       Impact factor: 5.455

Review 2.  Can Diet Prevent Urological Cancers? An Update on Carotenoids as Chemopreventive Agents.

Authors:  Tomasz Konecki; Aleksandra Juszczak; Marcin Cichocki
Journal:  Nutrients       Date:  2022-03-25       Impact factor: 5.717

Review 3.  Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.

Authors:  Dominique Reed; Komal Raina; Rajesh Agarwal
Journal:  NPJ Precis Oncol       Date:  2018-07-25

Review 4.  Carotenoids: How Effective Are They to Prevent Age-Related Diseases?

Authors:  Bee Ling Tan; Mohd Esa Norhaizan
Journal:  Molecules       Date:  2019-05-09       Impact factor: 4.411

5.  Effects of β-Cryptoxanthin on Improvement in Osteoporosis Risk: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Sun Jo Kim; Nguyen Hoang Anh; Nguyen Co Diem; Seongoh Park; Young Hyun Cho; Nguyen Phuoc Long; In Guk Hwang; Johan Lim; Sung Won Kwon
Journal:  Foods       Date:  2021-02-02

Review 6.  Plant Bioactives and the Prevention of Prostate Cancer: Evidence from Human Studies.

Authors:  Tracey L Livingstone; Gemma Beasy; Robert D Mills; Jenny Plumb; Paul W Needs; Richard Mithen; Maria H Traka
Journal:  Nutrients       Date:  2019-09-18       Impact factor: 5.717

Review 7.  The role of nutritional interventions in prostate cancer: A review.

Authors:  Mohammad Reza Nowroozi; Ehsan Ghaedi; Amir Behnamfar; Erfan Amini; Seyed Ali Momeni; Maryam Mahmoudi; Nima Rezaei; Saied Bokaie; Laleh Sharifi
Journal:  J Res Med Sci       Date:  2021-05-27       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.